Actrapid Vials 100 ml

Actrapid Vials 100 ml

Description:

Actrapid is a short-acting human insulin used for the treatment and control of diabetes mellitus. It contains soluble neutral human insulin and is typically administered by subcutaneous injection as part of an intensive insulin regimen. Actrapid helps lower and control blood glucose levels after meals, supporting effective diabetes management in adults and children with type 1 and type 2 diabetes. The product name here refers to Actrapid in vial form (100 ml total volume), designed for use with insulin syringes or compatible insulin delivery systems under medical supervision.

Indications:

• Adjunct to diet and exercise to improve glycemic control in adults and children with type 1 diabetes mellitus.
• Adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus when oral antidiabetic agents are insufficient or not appropriate.
• Management of hyperglycemia requiring insulin therapy, including in hospital settings under close medical supervision.
• Control of postprandial (after-meal) blood glucose excursions as part of a basal–bolus insulin regimen.

Active Ingredients / Key Components:

• Insulin human (soluble, neutral) – 100 iu/ml (exact concentration based on standard Actrapid HM formulation)
• Other excipients (typical for Actrapid HM may include: zinc chloride, glycerol, metacresol, sodium hydroxide/hydrochloric acid for pH adjustment, water for injections). Exact full excipient list for this specific 100 ml vial presentation is not available in the provided information.

Dosage & Administration / How to Use:

• Dosage is individual and must be determined by a physician based on blood glucose monitoring, type of diabetes, body weight, diet, physical activity, and concomitant medications.
• Actrapid is usually administered subcutaneously, typically in the abdominal wall, thigh, buttock, or upper arm. Rotate injection sites within the same region to reduce risk of lipodystrophy.
• Actrapid is a short-acting insulin and is generally injected 30 minutes before a meal or carbohydrate-containing snack, as directed by your healthcare provider.
• It is commonly used as the prandial (meal-time) component in a basal–bolus regimen together with intermediate- or long-acting insulin for 24-hour coverage.
• Use only clear, colorless solution. Do not use if the insulin appears cloudy, thickened, or contains particles.
• Use sterile insulin syringes or compatible insulin delivery systems appropriate for 100 iu/ml insulin. Follow your healthcare provider’s training on correct injection technique.
• Never share vials, syringes, or needles with others to avoid transmission of infections.
• Adjustments in dose may be required during illness, changes in physical activity, diet, or when adding/stopping other medications. Always consult your doctor before making changes.

Clinical Benefits:

• Provides reliable short-acting insulin coverage to control postprandial (after-meal) blood glucose levels.
• Helps improve overall glycemic control in patients with type 1 and type 2 diabetes when used as prescribed.
• Supports reduction of diabetes-related complications associated with chronic hyperglycemia, such as neuropathy, nephropathy, and retinopathy, when part of an appropriate treatment plan.
• Flexible use in hospital and outpatient settings, allowing individualized dosing and combination with basal insulin regimens.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to human insulin or any of the excipients.
• Do not use during episodes of hypoglycemia (low blood sugar). Blood glucose must be corrected before administration.
• Use with extreme caution in patients with renal or hepatic impairment; dose adjustments and close monitoring may be required.
• Beta-blockers and some other medications may mask symptoms of hypoglycemia. Inform your doctor about all medicines you are taking.
• Alcohol may enhance or reduce the hypoglycemic effect of insulin; limit and monitor alcohol intake.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding; insulin requirements may change and close monitoring is necessary.
• Use with caution in elderly patients and those at higher risk of severe hypoglycemia; frequent blood glucose monitoring is recommended.
• Do not change insulin type, strength, or dosing regimen without medical supervision, as this may lead to hyperglycemia or hypoglycemia.
• Keep out of reach of children.

Side Effects:

• Very common: Hypoglycemia (low blood sugar), which may present with symptoms such as sweating, tremor, palpitations, hunger, headache, confusion, irritability, or dizziness. Severe hypoglycemia can lead to loss of consciousness, seizures, or coma and requires urgent medical attention.
• Common: Injection site reactions (redness, pain, itching, swelling, bruising) which are usually mild and transient.
• Less common: Lipodystrophy (thickening or thinning of the skin/fat at injection sites) when injection sites are not rotated properly.
• Rare: Allergic reactions, including generalized skin rash, itching, shortness of breath, rapid heartbeat, or swelling of face, lips, tongue, or throat. Seek immediate medical help if signs of severe allergy occur.
• Fluid retention and edema may occur, especially when improving previously poor metabolic control.
• Contact your healthcare provider if you experience persistent or severe side effects, or if your blood glucose becomes difficult to control.

Storage Instructions:

Store unopened vials in a refrigerator at 2–8 °c. Do not freeze and do not place near the freezer compartment or cooling element. If a vial has been frozen, it must not be used. Once in use, follow the storage instructions provided in the official package leaflet; typically, in-use vials may be kept at room temperature (below 25–30 °c) for a limited period as specified by the manufacturer. Protect from direct sunlight and excessive heat. Keep container tightly closed. Keep out of reach of children.

Specifications:

• Product type: Injectable human insulin (short-acting)
• Concentration: 100 iu/ml
• Form: Solution for injection in vial
• Total volume: 100 ml vial (suitable for multiple doses under medical supervision)
• Route of administration: Primarily subcutaneous; may be used intravenously in specific clinical settings under strict medical supervision (hospital use only).

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.